All blog posts
Total 167 results for
Showing 12 out of 167 results
27 4月 2026
The EU Pharma Package is finally here – here's the settled position on key areas
12 3月 2026
Snapshot: Key European pharma regulatory, IP and competition developments from 2025 for the pharmaceutical sector
19 1月 2026
Where is the UPC after two and a half years - and what to expect in 2026?
15 12月 2025
A new era for EU pharmaceutical law: political agreement reached on the reform
26 11月 2025
FRAND interim licensing – where are the limits?
03 9月 2025
UPC Court of Appeal confirms that late-filed costs applications are inadmissible and in refusing reference to the CJEU provides guidance on what it will refer
31 7月 2025
EU Regulatory Reform for Medicinal Products: Bolar exemption
21 7月 2025
Trends emerging as the UPC enters its third year
13 5月 2025
EU Regulatory Reform for Medicinal Products: Changes to MAs, supply, and transparency
30 4月 2025
EU Regulatory Reform for Medicinal Products: Review of new regulatory exclusivities
12 2月 2025
European Commission shelves proposed SEP regulation
05 11月 2024
Regulation of SEPs in Europe – where are we now?
Showing 12 out of 167 results
View moreKey contacts
Rebekah Gay
Partner, Head of Intellectual Property, Sydney
Laura Orlando
Managing Partner, Milan Office, Milan
Sue Gilchrist
Consultant, Sydney
雷鹏
科伟史密夫斐尔凯迈联营办公室合伙人, Mainland China and Shanghai
Alexandra Neri
Partner, Paris
Dr Ina vom Feld
Partner, Germany
Sebastian Moore
Partner, Head Intellectual Property, London and Milan
Rachel Montagnon
Knowledge Counsel, London